TESARO (NASDAQ: TSRO) and BeiGene (NASDAQ:BGNE) are both mid-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, analyst recommendations, earnings, institutional ownership, valuation, profitabiliy and risk.

Analyst Recommendations

This is a breakdown of current recommendations for TESARO and BeiGene, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
TESARO 0 7 14 0 2.67
BeiGene 0 0 5 0 3.00

TESARO presently has a consensus price target of $173.52, suggesting a potential upside of 37.53%. BeiGene has a consensus price target of $71.33, suggesting a potential downside of 3.20%. Given TESARO’s higher possible upside, analysts clearly believe TESARO is more favorable than BeiGene.

Risk & Volatility

TESARO has a beta of 1.62, suggesting that its stock price is 62% more volatile than the S&P 500. Comparatively, BeiGene has a beta of -1.19, suggesting that its stock price is 219% less volatile than the S&P 500.

Earnings & Valuation

This table compares TESARO and BeiGene’s revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
TESARO $47.60 million 142.77 -$398.82 million ($8.41) -15.00
BeiGene $393,000.00 7,448.69 -$145.93 million ($4.13) -17.84

BeiGene has higher revenue, but lower earnings than TESARO. BeiGene is trading at a lower price-to-earnings ratio than TESARO, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

55.7% of BeiGene shares are held by institutional investors. 34.6% of TESARO shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares TESARO and BeiGene’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
TESARO -910.35% -96.49% -65.48%
BeiGene N/A -55.31% -46.59%

Summary

BeiGene beats TESARO on 8 of the 13 factors compared between the two stocks.

About TESARO

TESARO, Inc. is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform. Rolapitant is a potent and long-acting neurokinin-1 receptor antagonist for the prevention of chemotherapy induced nausea and vomiting. Niraparib is an orally active and potent poly (adenosine diphosphate (ADP)-ribose) polymerase inhibitor. It has various ongoing clinical trials evaluating niraparib for the treatment of ovarian or breast cancers. It has initiated a Phase I, dose escalation study for its first immuno-oncology antibody, TSR-042, which targets Programmed cell death protein 1. It has commenced pre-clinical research for its antibody candidate targeting Lymphocyte-activation gene-3 andTSR-033. It has commenced a Phase I clinical trial of TSR-042.

About BeiGene

BeiGene, Ltd. is a clinical-stage biopharmaceutical company. The Company is focused in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. The Company had used its cancer biology platform to develop four clinical-stage drug candidates, such as BGB-3111, BGB-A317, BGB-290 and BGB-283, as of December 31, 2016. BGB-3111, BGB-290 and BGB-283 are its molecularly targeted agents and is its immuno-oncology agent. BGB-3111 is a potent and highly selective small molecule inhibitor of Bruton’s tyrosine kinase (BTK). BGB-283 is a molecule inhibitor of both the monomer and dimer forms of the RAF kinase. BGB-290 is a molecularly targeted, orally available, potent and highly selective inhibitor of the poly ADP ribose polymerase (PARP) family members. BGB-A317 is an investigational humanized monoclonal antibody against the immune checkpoint receptor, PD-1.

Receive News & Ratings for TESARO Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TESARO Inc. and related companies with MarketBeat.com's FREE daily email newsletter.